Joe Rabin, Editor

About the Author Joe Rabin, Editor

Joe is an intern at Smarter Analyst. He has written on a broad range of topics, including: financial trading, career development, cybersecurity, gamification, network access control, recreation and more., Inc. (AMZN) to Capture Significant U.S. Grocery Market Share by 2022: Cantor

Whole Foods Acquisition to to Bring $17B of Annualized Revenue to Amazon’s Table, Says Kip Paulson

Gilead Sciences, Inc. (GILD) Has Solid Catalysts for Continued Growth; William Blair Sets Fair Value at $87

Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu

Kite Pharma Inc (KITE): FDA Approval of Kymriah Is Good News for the Future of Axi-cel

Canaccord Positive on Safety Profile of Kite’s Axi-Cel

Catalyst Pharmaceuticals Inc (CPRX) Shakes Hands with FDA on SPA for Firdapse; SunTrust Chimes In

Though NDA Gets Stalled, Analyst Says Catalyst “Still on Track”

Progenics Pharmaceuticals, Inc. (PGNX) Delay in NDA Filing Dose Not Reflect an Issue with Azedra Drug: Cantor

Commercial Revenues Are Likely in 2018 Despite Modest Delay in Filing

Himax Technologies, Inc. (ADR) (HIMX) Partnership With QUALCOMM, Inc. (QCOM) Takes 3D Sensing To Next Level: Top Analyst

HIMX Optics Module and QCOM Computer Vision Algorithms Make for Good Allies

Best Buy Co Inc (BBY) to Lose Ground Long-Term Against Major Online Retailers

Buybacks Not Enough to Spur EPS Gains Down the Line

Freeport-McMoran Inc (FCX) Grasberg Not a Done Deal; Berenberg Suggest Risks Remain

In Any Agreement Between Freeport and Indonesian Government, FCX Stands to Lose

Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) AUSTEDO Wins Key FDA Approval To Corner TD Market

TEVA’s Brand Drug Portfolio and Pipeline Are Undervalued, Says Analyst

Gilead Sciences, Inc. (GILD) Gets the Edge in Oncology Sector With Kite Pharma Take Over

Gilead Pivots to Cell Therapy; Cowen’s Phil Nadeau Weighs in

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts